Skip to main content
SpringerLink
Log in

Is Ribavirin Teratogenic in Humans? No Evidence So Far

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 08 July 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother. 2017;18:1235–42.

    Article  CAS  PubMed  Google Scholar 

  2. Núnez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Martín-Carbonero L, Romero M, García-Samaniego J, Soriano V. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther. 2005;10:657–62.

    PubMed  Google Scholar 

  3. Neukam K, Barreiro P, Macías J, Avellón A, Cifuentes C, Martín-Carbonero L, Echevarría JM, Vargas J, Soriano V, Pineda JA. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis. 2013;57:465–8.

    Article  CAS  PubMed  Google Scholar 

  4. Rallón NI, Morello J, Labarga P, Benito JM, Rodríguez-Nóvoa S, Vispo E, Barreiro P, Castro MÁ, Aguirrebengoa K, Pineda JA, Miralles P, Tellez MJ, Portu J, Miralles C, Ocampo A, Soriano V, Peginterferon Ribavirin Coinfection (PERICO) Team. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C. Clin Infect Dis. 2011;53:1291–5.

    Article  PubMed  Google Scholar 

  5. Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse A, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts S, Gane E, Stern J, Voss F, Baum P, Gallivan JP, Böcher W, Mensa F. ITPA genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for HCV infection. PLoS One. 2015;10:e0144004.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark P, Thompson A, Shianna K, Vispo E, McHutchison J, Goldstein D, Soriano V. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis. 2012;205:376–83.

    Article  CAS  PubMed  Google Scholar 

  7. Esposito I, Benítez-Gutiérrez L, Treviño A, Arias A, Citores MJ, Requena S, Soriano V, Cuervas-Mons V, de Mendoza C. Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C. Antivir Ther. 2017. doi:10.3851/IMP3138 (Epub ahead of print).

    PubMed  Google Scholar 

  8. Maddrey W. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999;19(Suppl. 1):67–75.

    CAS  PubMed  Google Scholar 

  9. Mishkin D, Deschênes M. Conception soon after discontinuing interferon/ribavirin therapy: a successful outcome. Am J Gastroenterol. 2001;96:2285–6.

    Article  CAS  PubMed  Google Scholar 

  10. Sinclair S, Jones J, Miller R, Greene M, Kwo P, Maddrey W. The Ribavirin Pregnancy Registry: an interim analysis of potential teratogenicity at the mid-point of enrollment. Drug Saf. 2017. doi:10.1007/s40264-017-0566-6 (Epub ahead of print).

    PubMed  Google Scholar 

  11. Hegenbarth K, Maurer U, Kroisel PM, Fickert P, Trauner M, Stauber R. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastroenterol. 2001;96:2286–7.

    Article  CAS  PubMed  Google Scholar 

  12. Bianca S, Ettore G. Male periconceptional ribavirin-interferon alpha-2b exposure with no adverse fetal effects. Birth Defects Res A Clin Mol Teratol. 2003;67:77–8.

    Article  CAS  PubMed  Google Scholar 

  13. De Santis M, Carducci B, Cavaliere AF, De Santis L, Lucchese A, Straface G, Caruso A. Paternal exposure to ribavirin: pregnancy and neonatal outcome. Antivir Ther. 2003;8:73–5.

    PubMed  Google Scholar 

  14. Rezvani M, Koren G. Pregnancy outcome after exposure to injectable ribavirin during embryogenesis. Reprod Toxicol. 2006;21:113–5.

    Article  CAS  PubMed  Google Scholar 

  15. Labarga P, Pinilla J, Cachorro I, Ruiz Y. Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy. Reprod Toxicol. 2007;24:414–6.

    Article  CAS  PubMed  Google Scholar 

  16. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105:140–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Unit, La Paz University Hospital and Medical School, Autonomous University, Madrid, Spain

    Vicente Soriano & Pablo Barreiro

  2. Calle Dr. J. J. Lopez Ibor 16, 28035, Madrid, Spain

    Vicente Soriano

  3. Hospital Carlos III, Madrid, Spain

    Pablo Barreiro

Authors
  1. Vicente Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pablo Barreiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vicente Soriano.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this commentary.

Conflict of interest

Vicente V. Soriano has previously received speaker fees from Gilead, AbbVie, Merck, Roche, and Janssen. Pablo Barreiro has no conflicts of interest directly relevant to the content of this commentary.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soriano, V., Barreiro, P. Is Ribavirin Teratogenic in Humans? No Evidence So Far. Drug Saf 40, 1163–1165 (2017). https://doi.org/10.1007/s40264-017-0597-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-017-0597-z

Search

Navigation